Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study.
Sergio Muñoz-MartínezVíctor SapenaAlejandro FornerJordi BruixMarco Sanduzzi-ZamparelliJose RíosMohamed BouattourMohamed El KassasCassia R G LealTudor MocanJean Charles NaultRogerio C P AlvesHelen L ReevesLeonardo Gomes da FonsecaIgnacio García-JuárezDavid James PinatoMaria VarelaSaleh A AlqahthaniMário Reis Alvares-DA-SilvaJuan C BandiLorenza RimassaMar LozanoJesús M González-SantiagoFrank TackeMargarita SalaMaría AndersAnja LachenmayerFederico PiñeroAlex FrançaMaria GuarinoAlessandra ElveviGiuseppe CabibboMarkus Peck-RadosavljevicÁngela RojasMercedes VergaraChiara BraconiSonia Pascual-BartoloméChristie PerellóVivianne MelloCarlos Rodríguez-LopeJuan AcevedoRosanna VillaniClemence HollandeValérie VilgrainAhmed TawheedCarmem Ferguson TheodoroZeno SparchezLorraine BlaiseDaniele E Viera-AlvesRobyn WatsonFlair J CarrilhoCarlos Moctezuma-VelazquezAntonio D'AlessioMassimo IavaroneMaria ReigPublished in: Liver international : official journal of the International Association for the Study of the Liver (2022)
This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.